Atherosclerosis
Volume 194, Issue 1 , Pages 112-115 , September 2007

LGALS2 functional variant rs7291467 is not associated with susceptibility to myocardial infarction in Caucasians

  • Massimo Mangino

      Affiliations

    • Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield Hospital, Groby Road, Leicester LE3 9QP, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 116 256 3048; fax: +44 116 287 5792.
    • ,
  • Peter Braund

      Affiliations

    • Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield Hospital, Groby Road, Leicester LE3 9QP, UK
    • ,
  • Ravi Singh

      Affiliations

    • Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield Hospital, Groby Road, Leicester LE3 9QP, UK
    • ,
  • Rick Steeds

      Affiliations

    • Department of Cardiology, Royal Hallamshire Hospital, Sheffield, UK
    • ,
  • John R. Thompson

      Affiliations

    • Departments of Health Sciences, University of Leicester, Leicester, UK
    • ,
  • Kevin Channer

      Affiliations

    • Department of Cardiology, Royal Hallamshire Hospital, Sheffield, UK
    • ,
  • Nilesh J. Samani

      Affiliations

    • Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield Hospital, Groby Road, Leicester LE3 9QP, UK

Received 7 August 2006 ,Revised 3 October 2006 ,Accepted 6 October 2006.

References 

  1. Bonow RO, Smaha LA, Smith SC, Mensah GA, Lenfant C. World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation. 2002;106:1602–1605
  2. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 1994;330:1041–1046
  3. Jefferson BK, Topol EJ. Molecular mechanisms of myocardial infarction. Curr Probl Cardiol. 2005;30:333–374
  4. Lusis AJ, Mar R, Pajukanta P. Genetics of atherosclerosis. Annu Rev Genomics Hum Genet. 2004;5:189–218
  5. Watkins H, Farrall M. Genetic susceptibility to coronary artery disease: from promise to progress. Nat Rev Genet. 2006;7:163–173
  6. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004;36:233–239
  7. Wang L, Fan C, Topol SE, Topol EJ, Wang Q. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science. 2003;302:1578–1581
  8. Ozaki K, Ohnishi Y, Iida A, et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet. 2002;32:650–654
  9. Helgadottir A, Gretarsdottir S, St Clair D, et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet. 2005;76:505–509
  10. Lohmussaar E, Gschwendtner A, Mueller JC, et al. ALOX5AP gene and the PDE4D gene in a central European population of stroke patients. Stroke. 2005;36:731–736
  11. Kajimoto K, Shioji K, Ishida C, et al. Validation of the association between the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a Japanese population. Circ J. 2005;69:1029–1034
  12. PROCARDIS C. A trio family study showing association of the lymphotoxin-alpha N26 (804A) allele with coronary artery disease. Eur J Hum Genet 2004;12:770–4.
  13. Bhagavatula MR, Fan C, Shen GQ, et al. Transcription factor MEF2A mutations in patients with coronary artery disease. Hum Mol Genet. 2004;13:3181–3188
  14. Gonzalez P, Garcia-Castro M, Reguero JR, et al. The Pro279Leu variant in the transcription factor MEF2A is associated with myocardial infarction. J Med Genet. 2006;43:167–169
  15. Lusis AJ. Atherosclerosis. Nature. 2000;407:233–241
  16. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–874
  17. Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol. 2003;91:3A–6A
  18. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126
  19. Ozaki K, Inoue K, Sato H, et al. Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro. Nature. 2004;429:72–75
  20. Steeds R, Adams M, Smith P, Channer K, Samani NJ. Distribution of tissue plasminogen activator insertion/deletion polymorphism in myocardial infarction and control subjects. Thromb Haemost. 1998;79:980–984
  21. Brouilette S, Singh RK, Thompson JR, Goodall AH, Samani NJ. White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol. 2003;23:842–846
  22. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 1979;59:607–9.
  23. Livak KJ. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal. 1999;14:143–149
  24. Gauderman WJ. Sample size requirements for matched case–control studies of gene-environment interaction. Stat Med. 2002;21:35–50
  25. Petersen S, Peto V, Scarbough P, Rayner M. Coronary heart disease statistics. Br Heart Foundation. 2005;46
  26. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–265
  27. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet. 2003;361:865–872
  28. Guo D, Li M, Zhang Y, et al. A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet. 2004;36:837–841
  29. Smyth DJ, Howson JM, Lowe CE, et al. Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes. Nat Genet. 2005;37:110–111author reply 2-3
  30. Park Y, Park S, Kang J, Yang S, Kim D. Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes. Nat Genet. 2005;37:112;author reply -3
  31. Qu H, Bharaj B, Liu XQ, et al. Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes. Nat Genet. 2005;37:111–112author reply 2–3
  32. Jennings CE, Owen CJ, Wilson V, Pearce SH. No association of the codon 55 methionine to valine polymorphism in the SUMO4 gene with Graves’ disease. Clin Endocrinol (Oxf). 2005;62:362–365
  33. Kim TY, Park YJ, Hwang JK, et al. A C/T polymorphism in the 5′-untranslated region of the CD40 gene is associated with Graves’ disease in Koreans. Thyroid. 2003;13:919–925
  34. Heward JM, Simmonds MJ, Carr-Smith J, et al. A single nucleotide polymorphism in the CD40 gene on chromosome 20q (GD-2) provides no evidence for susceptibility to Graves’ disease in UK Caucasians. Clin Endocrinol (Oxf). 2004;61:269–272

PII: S0021-9150(06)00607-1

doi: 10.1016/j.atherosclerosis.2006.10.004

Atherosclerosis
Volume 194, Issue 1 , Pages 112-115 , September 2007

Article Tools

* Image Usage & Resolution